Novelix Pharmaceuticals Ltd
NSE: BSE: 536565
₹55.95
(1.18%)
Fri, 08 May 2026, 04:36 pm
Market Cap978.16M
PE Ratio45.95
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KNovelix Pharmaceuticals Analysis
dividend
- Unable to calculate sustainability of dividends as Trimurthi has not reported any payouts.
- Unable to evaluate Trimurthi's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Trimurthi's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Trimurthi is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Trimurthi has been profitable on average in the past, therefore cash runway is not a concern.
- Trimurthi has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 13x debt.
- Trimurthi's cash and other short term assets cover its long term commitments.
- Trimurthi's level of debt (7.6%) compared to net worth is satisfactory (less than 40%).
- Operating cash flow is negative therefore debt is not well covered.
- The level of debt compared to net worth has increased over the past 5 years (0% vs 7.6% today).
- High level of physical assets or inventory.
management
- The tenure for the Trimurthi board of directors is about average.
- Arun's remuneration is lower than average for companies of similar size in India.
- Arun's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Trimurthi management team is about average.
misc
- Trimurthi is not covered by any analysts.
- BSE:536565 has not traded for 6 days.
past
- Unable to compare Trimurthi's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Trimurthi does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Trimurthi has efficiently used its assets last year compared to the IN Healthcare industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Trimurthi improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Trimurthi has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Trimurthi's 1-year growth to the IN Healthcare industry average as it is not currently profitable.
value
- Trimurthi is good value based on assets compared to the IN Healthcare industry average.
- Trimurthi is loss making, we can't compare its value to the IN Healthcare industry average.
- Trimurthi is loss making, we can't compare the value of its earnings to the India market.
- 536565 underperformed the Healthcare industry which returned 9.1% over the past year.
- 536565 underperformed the Market in India which returned -14.5% over the past year.
- BSE:536565 is down -2.6% underperforming the Healthcare industry which returned 5.4% over the past month.
- BSE:536565 is down -2.6% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800